18F-LNC1001 Injection
Oncology (Target not specified, likely PSMA or FAP related)
Phase 3Active
Key Facts
Indication
Oncology (Target not specified, likely PSMA or FAP related)
Phase
Phase 3
Status
Active
Company
About Yantai LNC Biotechnology
A clinical-stage biotech developing innovative radiopharmaceuticals for cancer theranostics, backed by Dongcheng Pharmaceutical Group.
View full company profile